EUVIMEDSkopri EUVIMED
CrossrefKarta ta’ informazzjoni

Multiplex detection of circulating biomarkers for early and progressive stages of colorectal cancer

Aleksandr A. Rozhkov, Marina V. Prokhorova, Marina I. Sekacheva

Science and Innovations in Medicine · 2026-10-09 · 11 (4) · 293-300

DOI: 10.35693/sim704767 ↗
AstrattDettalji biblijografiċi

Astratt

Aim: to evaluate the diagnostic potential of a panel of serum biomarkers for detecting CRC at different stages using multiplex xMAP technology. Material and methods. The study included serum samples from 137 patients with CRC and 100 healthy donors. The concentrations of ten biomarkers (L1CAM, CA9, mesothelin, midkine, hepsin, kallikrein-6, TGM2, ALDH1A1, EpCAM and CD44) were determined using the Luminex MAGPIX® platform. Statistical analysis was performed using nonparametric methods. Results. It was found that the concentrations of the following biomarkers were significantly elevated in CRC patients compared to the control group (p ≤ 0.001): midkine (232.54 vs. 154.96 pg/mL), mesothelin (3.17 vs. 2.49 pg/mL), hepsin (0.23 vs. 0.14 pg/mL) and kallikrein-6 (1106.35 vs. 872.47 pg/mL); the levels of L1CAM (1.05 vs. 1.23 pg/mL) and CA9 (20.52 vs. 12.69 pg/mL) also showed significant differences (p ≤ 0.05). Stage-specific analysis revealed that midkine, mesothelin, CA9, and TGM2 were associated with early stages of CRC, whereas kallikrein-6 and hepsin were associated with tumor progression and metastasis. At the same time, some biomarkers (EpCAM, CD44, ALDH1A1) did not show statistically significant differences between groups. Conclusion. The obtained results indicate the potential of multiplex analysis of serum biomarkers for the early detection of CRC. A combination of biomarkers reflecting different mechanisms of tumor development may improve diagnostic accuracy and serve as a basis for the development of non-invasive screening tests.

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.

Ara t-tariffi →